DBV Technologies (ADR) Logo
US23306J3095
A40WEX

DBV Technologies (ADR)

Forecast

The analysts' average price target is €42.23 (+415.00%). The median is €43.76 (+433.66%).

Buy
  10
Hold
  4
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, DBV Technologies (ADR) had revenue of €0 and net profit of -€56.94M

(EUR) September 2026
YoY
Revenue 0 -
Gross profit 0 100.00%
Net profit -56.94M 102.40%
EBITDA -54.03M 101.31%

Fundamentals

Metric Value
Market capitalization
€205.42M
Number of shares
23.92M
52-week high/low
€23.87 - €7.87
Dividends No
Beta
-0.21
P/E ratio
-3.25
PEG ratio
-0.05
P/B ratio
6.01
P/S ratio
106.78

Company profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Name
DBV Technologies (ADR)
CEO
Daniel Tassé
Website
IPO
10/22/2014
Employees 125
🍪

Parqet  uses cookies. Learn more